PR Newswire - Halia Therapeutics Announces Positive Phase 2a Dat...
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed across ESA-refractory and ESA-intolerant patients, and across m...
Read More

ภาษาไทย
English